Published on April 27, 2004 at 11:26 PM
Results of a new multicenter U.S. study of almost 1,900 patients experiencing more than 3,400 migraine attacks confirm that treatment with ZOMIG(R) (zolmitriptan) Nasal Spray provides a very fast onset of action and long-lasting relief from migraine headache and associated symptoms.
Findings from an open-label trial also presented today demonstrate that patients are satisfied with the migraine relief received from ZOMIG Nasal Spray, with the majority of patients willing to continue its use.
Data were presented today at the American Academy of Neurology (AAN) 56th Annual Meeting. "Many migraine sufferers typically cite fast-acting relief as a high priority in choosing a migraine therapy," said Jan Lewis Brandes, MD, Clinical Instructor, Department of Neurology, Vanderbilt University School of Medicine and head of Nashville Neuroscience Group, and an investigator of the U.S. study. "In this trial, some patients began experiencing relief from their symptoms as early as 15 minutes after using zolmitriptan nasal spray."